NASDAQ: GLTOGalecto Inc Stock
$3.37+0.00 (+0%)
Updated Aug 19, 2025
GLTO Price
$3.37
Fair Value Price
N/A
Market Cap
$4.46M
52 Week Low
$2.01
52 Week High
$14.88
P/E
-0.26x
P/B
0.41x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$16.59M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.25
Operating Cash Flow
-$13M
Beta
1.26
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GLTO Overview
Galecto, Inc. is a clinical-stage biotechnology company developing molecules for the treatment of fibrosis, cancer, inflammation, and related diseases. Its research centers on the use of modulators proteins galectin-3 and LOXL-2. The company was founded in 2011 and is based in Boston, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GLTO's potential to beat the market
- GLTO doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GLTO
RankedUnranked of 482
RankedUnranked of 482
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.45 | A | |
| $38.94 | A | |
| $12.03 | A |
Be the first to know about important GLTO news, forecast changes, insider trades & much more!
GLTO News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GLTO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GLTO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GLTO is good value based on its book value relative to its share price (0.41x), compared to the US Biotechnology industry average (4.49x)
P/B vs Industry Valuation
GLTO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GLTO due diligence checks available for Premium users.
Valuation
GLTO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.26x
Industry
-111.82x
Market
35.19x
GLTO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.41x
Industry
4.49x
GLTO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GLTO's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.4M
Profit Margin
0%
GLTO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$13.7M
Liabilities
$2.7M
Debt to equity
0.25
GLTO's short-term assets ($13.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GLTO's short-term assets ($13.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GLTO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GLTO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.2M
Investing
$0.0
Financing
$0.0
GLTO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GLTO vs Biotech Stocks
Galecto Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.